Exhibit 99.1


                        Possis Medical Inc. Receives FDA
                   Approval for Fetch(TM) Aspiration Catheter

         New Device Broadens Company's Thrombus Management Product Line


    MINNEAPOLIS--(BUSINESS WIRE)--Oct. 9, 2006--Possis Medical, Inc.
(NASDAQ--NMS:POSS) today announced it has received 510(k) clearance
from the U.S. Food and Drug Administration (FDA) for its new Fetch(TM)
Aspiration Catheter. Utilizing catheter technology from the company's
premier AngioJet(R) Rheolytic(TM) Thrombectomy System, the Fetch
Aspiration Catheter offers physicians another alternative for the
aspiration of small, fresh blood clots (thrombus) and other embolic
debris from arteries.

    "Our goal is to offer physicians a full range of solutions for
thrombus removal," said Robert Dutcher, chairman, president and CEO of
Possis Medical. "Our AngioJet Thrombectomy System continues to grow as
the market leader and gold standard for thrombectomy in peripheral,
coronary and dialysis access interventions. Although manual aspiration
catheters such as the Fetch catheter offer much less thrombus removal
capability than the AngioJet Thrombectomy System, the addition of the
Fetch Aspiration Catheter provides physicians with a quick and simple
means to aspirate small amounts of fresh thrombus and embolic debris
from small coronary arteries.

    "As the recognized leader in thrombus management, the addition of
the Fetch Aspiration Catheter to our product line further enhances our
position as an increasingly valuable partner to our 1,800 current
customers who deal with thrombus," said Dutcher.

    According to Possis, the rapid exchange Fetch Aspiration Catheter
uses an industry-standard syringe as its aspiration source. To provide
the flexibility and handling that interventional procedures require,
Fetch features an advanced braided shaft design used in other AngioJet
thrombectomy catheters marketed by Possis. Additionally, the Fetch
catheter is 0.014" guidewire and 6F guide catheter compatible.

    "Our proprietary convex tip design, combined with a small outer
diameter and hydrophilic coating, minimizes vessel trauma and enhances
deliverability. In-house testing showed that the Fetch catheter often
outperforms other currently available aspiration devices in the key
areas of trackability, contrast injection and aspiration rate. Fetch
is a valuable addition to our expanding range of thrombus management
and broader endovascular therapies," said Dutcher.

    Possis will market the Fetch Aspiration Catheter in the Unites
States through the company's sales organization and internationally
through an established network of Possis distributors. Anticipated
revenue from Fetch catheter sales is reflected in the company's
current guidance.

    About Possis Medical, Inc.

    Possis Medical, Inc., develops, manufactures and markets
pioneering medical devices for the large and growing cardiovascular
and vascular treatment markets. The company's AngioJet System is the
world's leading mechanical thrombectomy system with FDA approval to
remove large and small thrombus from coronary arteries, coronary
bypass grafts, peripheral arteries and A-V grafts and native fistulas.

    Certain statements in this press release constitute
"forward-looking statements" within the meaning of Federal Securities
Laws. Some of these statements relate to Fetch Aspiration Catheter and
AngioJet System product performance, market acceptance, regulatory
approvals, and new product introductions. These statements are based
on our current expectations and assumptions, and entail various risks
and uncertainties that could cause actual results to differ materially
from those expressed in such forward-looking statements, such as, the
effectiveness of our sales and marketing efforts, our ability to
effectively manage new product development timelines, and our ability
to generate suitable clinical data. A discussion of these and other
factors that could impact the Company's future results are set forth
in the cautionary statements included in the Company's Form 10-K for
the year ended July 31, 2005, filed with the Securities and Exchange
Commission.



    CONTACT: Possis Medical, Inc.
             JULES L. FISHER, Vice President, Finance and
             Chief Financial Officer, 763-450-8011
             jules.fisher@possis.com